A Study of Avastin (Bevacizumab) in Patients With Inflammatory or Locally Advanced Breast Cancer.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This single arm study will assess the efficacy and safety of sequential neoadjuvant chemotherapy and Avastin, before surgery and/or radiotherapy, in patients with inflammatory or locally advanced operable breast cancer. Patients will receive FEC, followed by paclitaxel, given concomitantly with Avastin (10mg/kg i.v. every 2 weeks). The anticipated time on study treatment is 3-12 months, and the target sample size is <100 individuals.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
female patients, >=18 years of age;
stage III, or inflammatory breast cancer;
ER/PgR positive or negative and HER-2 negative;
previous chemotherapy/endocrine therapy;
evidence of distant metastatic disease;
other primary tumors in last 5 years (except for adequately treated cancer in situ of the cervix, or basal cell skin cancer);
chronic daily treatment with >325mg/day aspirin, or >75mg/day clopidogrel.